It acquired rights to taligurase alfa, a form of the enzyme glucocerebrosidase in development for the treatment of Gaucher's disease, from Protalix Biotherapeutics in Carmiel, Israel. Protalix has ...

BIAL has reported the completion of the full dose regimen for the first subject in the multicentre Phase II ACTIVATE trial of the allosteric activator of beta-glucocerebrosidase (GCase), BIA 28 ...